Global Emerging Therapeutics for Hematological Malignancies Market 2022 - Industry Briefing

The global emerging therapeutics for hematological malignancies market is anticipated to increase by USD 12.0 billion till 2028 at an average annual growth of 13.4 percent as per the latest report by.

This industry report offers market estimates of the global market, followed by a detailed analysis of the type, indication, and region. The global market data on emerging therapeutics for hematological malignancies can be segmented by type: CAR T-cell therapies, monoclonal antibodies. The monoclonal antibodies segment was the largest contributor to the global emerging therapeutics for hematological malignancies market in 2021. Emerging therapeutics for hematological malignancies market is further segmented by indication: leukemia, lymphoma, multiple myeloma. Based on region, the emerging therapeutics for hematological malignancies market is segmented into: Asia Pacific, Europe, North America, Rest of the World (RoW).

The CAR T-cell therapies market is further segmented into tisagenlecleucel (Kymriah), axicabtagene ciloleucel (Yescarta), brexucabtagene autoleucel (Tecartus), others. Furthermore, the monoclonal antibodies market has been categorized into blinatumomab (Blincyto), brentuximab vedotin (Adcetris), daratumumab (Darzalex), inotuzumab ozogamicin (Besponsa), obinutuzumab (Gazyva), sintilimab (Tyvyt), others.

The global emerging therapeutics for hematological malignancies market is highly competitive. Top players covered in Global Emerging Therapeutics for Hematological Malignancies Market Study are AbbVie Inc., Amgen Inc., Bristol-Myers Squibb Company (BMS), F. Hoffmann-La Roche AG, Gilead Sciences Inc., GlaxoSmithKline plc, Immune-Onc Therapeutics Inc., Johnson & Johnson, Merck & Co. Inc., Novartis AG, Pfizer Inc., Sanofi S.A., Takeda Pharmaceutical Company Limited.

The data-centric report focuses on market trends, status and outlook for segments. With comprehensive market assessment across the major geographies, the report is a valuable asset for the existing players, new entrants and the future investors.

Why buy this report?
- Get a detailed picture of the Global Emerging Therapeutics for Hematological Malignancies Market
- Identify segments/areas to invest in over the forecast period in the Global Emerging Therapeutics for Hematological Malignancies Market
- Understand the competitive environment, the markets leading players
- The market estimate for ease of analysis across scenarios in Excel format.
- Strategy consulting and research support for three months.
- Print authentication provided for the single-user license.

Part 1. Summary

Part 2. Introduction
Study period
Geographical scope
Market segmentation

Part 3. Emerging therapeutics for hematological malignancies market overview

Part 4. Market breakdown by type
CAR T-cell therapies
Monoclonal antibodies

Part 5. Market breakdown by indication
Leukemia
Lymphoma
Multiple myeloma

Part 6. Market breakdown by region
Asia Pacific
Europe
North America
Rest of the World (RoW)

Part 7. Key companies
AbbVie Inc.
Amgen Inc.
Bristol-Myers Squibb Company (BMS)
F. Hoffmann-La Roche AG
Gilead Sciences, Inc.
GlaxoSmithKline plc
Immune-Onc Therapeutics, Inc.
Johnson & Johnson
Merck & Co., Inc.
Novartis AG
Pfizer Inc.
Sanofi S.A.
Takeda Pharmaceutical Company Limited

Part 8. Methodology

2024 Global Hepatitis Diagnostic Testing Markers Supplier Shares and Strategies Volume and Sales Segment Forecasts for Immunodiagnostic and Molecular Diagnostic Procedures--Hospitals Blood Banks Commercial Labs POC Locations

2024 Global Hepatitis Diagnostic Testing for 10 Markers: Supplier Shares and Strategies, Volume and Sales Segment Forecasts for Immunodiagnostic and Molecular Diagnostic Procedures--Hospitals, Blood Banks, Commercial Labs, POC Locations The

USD 7500 View Report

2024 Global PSA Testing Market Supplier Shares and Strategies Volume and Sales Segment Forecasts Emerging Opportunities

2024 Global PSA Testing Market: US, Europe, Japan--Supplier Shares and Strategies, Volume and Sales Segment Forecasts, Emerging Opportunities This unique report from provides information and analysis not available from any

USD 2450 View Report

Global Hematological Malignancies Emerging Therapeutics Market 2023

The global 3D protein structure analysis market was valued at $1.09 billion in 2022 and is projected to reach $1.83 billion by 2029, with a 7.4% CAGR from 2023-2029. Market

USD 2850 View Report

Global Emerging Diagnostic Imaging Market Research Report

The emerging diagnostic imaging market is segmented on the basis of applications such as advanced conventional technologies, remote diagnostics, point-of-care diagnostics, nuclear medicine, biomarkers, imaging agents and other emerging technologies.

USD View Report

Fill The Form For Sample Request

Note : * Kindly provide us with your company id and get the sample reports at the earliest.

There is no Reviews available